Weekly round-up: From a vaccine protein manufacturing collaboration, to the appointment of an orthopaedic devices expert…
MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus and Wacker Biotech, a contract development and manufacturing organisation, on Tuesday announced a collaboration to manufacture the active protein ingredients of MinervaX’s GBS vaccine.
MinervaX will scale up supply of its novel GBS vaccine, ahead of commencing phase III studies, while Wacker Biotech will manufacture the active vaccine protein ingredients and prepare for commercial supply following regulatory approval.
Biocomposites acquires remaining shares in the manufacturers of SYNICEM™ and Subiton products
Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, on Wednesday announced the acquisition of the remaining shares in Laboratorios SL S.A. and Synergie Ingénierie Médicale S.A.R.L. – gaining full control of the SYNICEMTM and Subiton product ranges.
The SYNICEMTM and Subiton preformed antibiotic-loaded spacers overcome the challenges of traditional intra-operative moulded and handmade spacers, supporting surgeons’ revisions of the hip, knee and shoulder to preserve articular space and aid the treatment of infection.
Poolbeg Pharma plc – Interim results for the six months to 30 June 2024
Poolbeg Pharma, a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, on Wednesday announced its unaudited interim results for the six months to 30 June 2024.
Highlights include its lead development candidate – POLB 001 – being on track with positive data demonstrating efficacy, and independent research endorsing a potential c.US$10bn market opportunity in cancer immunotherapy-induced Cytokine Release Syndrome.
Renovos Biologics strengthens its Board’s US expertise with appointment of Lisa Ferrara, Ph.D.
Renovos Biologics (Renovos), an investment of Biocomposites, on Thursday announced the appointment of Lisa Ferrara, Ph.D. Renovos Biologics (Renovos), an investment of Biocomposites, on Thursday announced the appointment of Lisa Ferrara, Ph.D. to its Board as a Non-Executive Director.
The appointment of Dr Ferrara, who has extensive experience in developing new orthopaedic devices in the USA and obtaining regulatory approval for them, comes as Southampton, UK-based Renovos advances the development of its lead product RENOVITE® BMP-2, a next-generation precision drugs carrier.
Novo Holdings publishes its Responsible Investment Report 2023
Novo Holdings launched its Responsible Investment Report on Wednesday, providing a comprehensive review of Novo Holdings’ activities and outlining how it strives to create long-term economic value while contributing positively to human health and the health of the planet.
The report highlights the progress Novo Holdings has made against the commitments that it has set to accelerate the green transition as part of its Strategy 2030. Further, the report outlines the Novo Holdings investment strategy, approach to responsible investment, and how ESG is integrated into the investment process, while analysing progress across Novo Holdings’ three key focus areas of Health, Planet and People.
The full report is available to read here.
Neuraxpharm’s partner, TG Therapeutics, announced new data for BRIUMVI® (ublituximab-xiiy)
TG Therapeutics announced updated data presentations, including new five-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, where TG Therapeutics and Neuraxpharm exhibited.
Data demonstrate that 92% of patients with relapsing multiple sclerosis were free from disability progression after five years of treatment.
Optimum TV
The ‘Countdown to Conference’ mini-series continues, with the latest episode featuring Francesco De Rubertis, co-founder and Partner at Medicxi. Francesco shared his invaluable insights about how the market for life science companies moves in waves, why M&A is more popular than IPOs right now, and his thoughts on the next big trends in the treatment of cancer and autoimmune diseases.
If you enjoyed watching, check out our YouTube channel where you can catch up on all episodes!
That’s all folks! We hope you are enjoying Optimum’s weekly round-ups; subscribe today so you never miss an edition.
